J.W. Cole Advisors Inc. Has $396,000 Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

J.W. Cole Advisors Inc. boosted its stake in Edwards Lifesciences Co. (NYSE:EWGet Rating) by 5.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,364 shares of the medical research company’s stock after purchasing an additional 170 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in Edwards Lifesciences were worth $396,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. American National Bank lifted its position in shares of Edwards Lifesciences by 99.1% during the first quarter. American National Bank now owns 233 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 116 shares in the last quarter. Core Alternative Capital increased its stake in shares of Edwards Lifesciences by 513.2% in the first quarter. Core Alternative Capital now owns 233 shares of the medical research company’s stock worth $27,000 after purchasing an additional 195 shares in the last quarter. Rinkey Investments purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth about $29,000. JJJ Advisors Inc. increased its stake in shares of Edwards Lifesciences by 79.1% in the first quarter. JJJ Advisors Inc. now owns 283 shares of the medical research company’s stock worth $33,000 after purchasing an additional 125 shares in the last quarter. Finally, Gemmer Asset Management LLC purchased a new position in shares of Edwards Lifesciences in the first quarter worth about $36,000. 81.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In other news, CEO Michael A. Mussallem sold 19,875 shares of the company’s stock in a transaction dated Thursday, July 14th. The shares were sold at an average price of $95.88, for a total value of $1,905,615.00. Following the sale, the chief executive officer now directly owns 166,853 shares of the company’s stock, valued at approximately $15,997,865.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, VP Donald E. Bobo, Jr. sold 6,725 shares of the company’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $90.94, for a total value of $611,571.50. Following the sale, the vice president now directly owns 62,561 shares of the company’s stock, valued at approximately $5,689,297.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael A. Mussallem sold 19,875 shares of the company’s stock in a transaction dated Thursday, July 14th. The stock was sold at an average price of $95.88, for a total transaction of $1,905,615.00. Following the completion of the sale, the chief executive officer now directly owns 166,853 shares in the company, valued at $15,997,865.64. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 66,253 shares of company stock valued at $6,550,960. 1.29% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Canaccord Genuity Group downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their target price for the stock from $115.00 to $106.00 in a research note on Friday, July 29th. Cowen reduced their price objective on shares of Edwards Lifesciences from $140.00 to $125.00 in a research note on Monday, July 11th. Truist Financial reduced their price objective on shares of Edwards Lifesciences from $140.00 to $120.00 and set a “buy” rating for the company in a research note on Wednesday, July 20th. Canaccord Genuity Group cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their price target for the stock from $115.00 to $106.00 in a research note on Friday, July 29th. Finally, Cowen cut their price target on shares of Edwards Lifesciences from $140.00 to $125.00 in a research note on Monday, July 11th. Three research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $126.19.

Edwards Lifesciences Trading Down 4.8 %

NYSE:EW opened at $88.83 on Tuesday. The company has a fifty day moving average of $98.20 and a 200 day moving average of $102.37. Edwards Lifesciences Co. has a 52 week low of $85.58 and a 52 week high of $131.73. The company has a quick ratio of 2.60, a current ratio of 3.37 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $55.07 billion, a P/E ratio of 38.45, a P/E/G ratio of 2.76 and a beta of 1.14.

Edwards Lifesciences (NYSE:EWGet Rating) last issued its quarterly earnings data on Thursday, July 28th. The medical research company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.64 by ($0.01). The company had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.40 billion. Edwards Lifesciences had a net margin of 27.18% and a return on equity of 24.77%. The firm’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.64 earnings per share. On average, research analysts predict that Edwards Lifesciences Co. will post 2.51 earnings per share for the current year.

Edwards Lifesciences Company Profile

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

See Also

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWGet Rating).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.